TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Pharmaceutical Company Limited Stock Deutsche Boerse AG
Equities
TKD
JP3463000004
Pharmaceuticals
|
Market Closed -
Other stock markets
|
After market 03:58:01 pm | |||
| 24.63 EUR | +0.12% |
|
24.78 | +0.63% |
| Jun. 06 | Former Takeda Employee Pleads Guilty to Defrauding Company | DJ |
| Jun. 06 | Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema | MT |
| Sales 2024 | 4,264B 27.18B 25.18B | Sales 2025 * | 4,252B 27.1B 25.11B | Capitalization | 6,640B 42.33B 39.21B |
|---|---|---|---|---|---|
| Net income 2024 | 144B 918M 851M | Net income 2025 * | 116B 742M 688M | EV / Sales 2024 | 1.54 x |
| Net Debt 2024 * | 3,771B 24.04B 22.27B | Net Debt 2025 * | 4,224B 26.93B 24.94B | EV / Sales 2025 * | 2.56 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
60
x | Employees | 49,095 |
| Yield 2024 |
4.49% | Yield 2025 * |
4.58% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 day | +0.75% | ||
| 1 week | +1.95% | ||
| Current month | +0.53% | ||
| 1 month | -0.69% | ||
| 3 months | -7.13% | ||
| 6 months | -3.98% | ||
| Current year | -4.31% |
1 week
24.43
24.88
1 month
23.8624.88
Current year
23.8627.59
1 year
23.8630.99
3 years
23.4131.14
5 years
23.2037.63
10 years
23.2050.45
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 24.63 | +0.12% | 0 |
| 24-06-06 | 24.6 | -0.20% | 552 |
| 24-06-05 | 24.65 | +0.69% | 20 |
| 24-06-04 | 24.48 | +0.20% | 28 |
| 24-06-03 | 24.43 | -0.29% | 0 |
Delayed Quote Deutsche Boerse AG, June 07, 2024 at 03:38 pm EDT
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-06-25
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,232
JPY
Average target price
4,768
JPY
Spread / Average Target
+12.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +45.82% | 754B | |
| +40.95% | 630B | |
| -6.16% | 352B | |
| +19.86% | 331B | |
| +9.32% | 298B | |
| +18.45% | 250B | |
| +11.88% | 217B | |
| -0.78% | 216B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 4502 Stock
- TKD Stock
